C4 Therapeutics, Inc.
A biopharmaceutical company developing targeted protein degradation medicines, a technology that harnesses the body's own protein-disposal machinery to destroy disease-causing proteins. Its lead programs target cancers and other serious diseases. The company was founded in 2015 as a spinout from Dana-Farber Cancer Institute, and its name reflects its focus on the "C4" family of E3 ligase enzymes that tag proteins for destruction.
Granted 2.7K · Bought 5.0K
Granted 1.4K
Granted 1.25M · Bought 10.0K
Granted 22.1K
Sold 176.6K
Granted 69.2K
Granted 435.8K
Granted 471.4K · Sold 10.0K
Granted 371.3K
Granted 341.8K · Sold 1.2K
Granted 341.8K
Granted 132.9K · Sold 85.4K
Granted 140.8K · Sold 25.0K
Granted 84.7K
Granted 71.5K
Granted 32.0K
Granted 93.8K · Sold 75.0K
Granted 1.4K · Bought 1.3K · Sold 6.0K
Bought 5.7K
Bought 5.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Cohen Marc ADirector · 11 transactions | — | 10.26Mas of Jan 2022 | 2.7K | 5.0K | — |
| Cohen Alain JDirector · 10 transactions | — | 9.62Mas of Apr 2022 | 1.4K | — | — |
| Hirsch AndrewPresident & CEO, Director · 21 transactions | — | 1.08M | 1.25M | 10.0K | — |
| Dubin GlennDirector · 12 transactions | — | 812.7Kas of Apr 2024 | 22.1K | — | — |
| Prokupets ElenaDirector · 30 transactions | — | 534.8Kas of Sep 2021 | — | — | 176.6K |
| Anderson Kenneth CarlDirector · 43 transactions | — | 525.4K | 69.2K | — | — |
| Downey BruceDirector · 2 transactions | — | 489.5Kas of Oct 2020 | — | — | — |
| Adams KendraChief Financial Officer · 18 transactions | — | 400.5K | 435.8K | — | — |
| Reyno LeonardChief Medical Officer · 11 transactions | — | 396.4K | 471.4K | — | 10.0K |
| Mahaney PaigeChief Scientific Officer · 7 transactions | — | 336.9K | 371.3K | — | — |
| Boyle Scott NChief Business Officer · 22 transactions | — | 306.1K | 341.8K | — | 1.2K |
| Schick KellyChief People Officer · 20 transactions | — | 299.9K | 341.8K | — | — |
| Fisher StewartChief Scientific Officer · 22 transactions | — | 130.7Kas of Sep 2024 | 132.9K | — | 85.4K |
| Siegel JolieChief Legal Officer · 19 transactions | — | 107.9Kas of Feb 2025 | 140.8K | — | 25.0K |
| Mossler MarkChief Accounting Officer · 5 transactions | — | 71.9K | 84.7K | — | — |
| Grogan Donna RoyDirector · 15 transactions | — | 71.5K | 71.5K | — | — |
| White LaurenChief Financial Officer · 6 transactions | — | 32.7Kas of Aug 2023 | 32.0K | — | — |
| Crystal AdamChief Medical Officer · 20 transactions | — | 20.1Kas of Jan 2023 | 93.8K | — | 75.0K |
| Salter MalcolmDirector · 15 transactions | — | 11.4Kas of Jan 2022 | 1.4K | 1.3K | 6.0K |
| Koppikar UtpalDirector · 1 transaction | — | 5.7Kas of Feb 2023 | — | 5.7K | — |
| McKee WilliamChief Financial Officer · 1 transaction | — | 5.3Kas of Oct 2020 | — | 5.3K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -351.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.